microdose tirzepatide schedule How to wean off tirzepatide: complete tapering guide Microdosing Tirzepatide: How It Works,

J Clin Endocrinol Metab (2012) 97(8):E141120.10.1210/jc.2012-1111 60 TuominenIHelivaaraERaitilaARautiainenMMehineMKatainenRet alAIP inactivation leads to pituitary tumorigenesis through defective Gi-cAMP signaling

Transitioning Between Medications Rather than taking them together, some providers recommend a bridge or transition

Study-related adverse events Adverse reactions reported in 5% of patients and occurring more frequently with Victoza compared with placebo included nausea (21.4% vs 4.4%), vomiting (12.1% vs 2.2%), diarrhea (7.1% vs 2.9%), constipation (5.7% vs 1.5%), increased lipase (15.0% vs 8.8%), GFR decreased (6.4% vs 5.1%), and headache (5.0% vs 2.9%)

We thank Mark Huising and Anthony McCall for their input